Pfizer’s Experimental Lung Cancer therapy fails to meet trial endpoints

Pfizer announced on Monday that its experimental drug, intended to supplant a widely used chemotherapy for a common type of lung cancer, did not achieve its primary goals in a recent clinical trial.

The drug, sigvotatug vedotin, was being evaluated as a potential replacement for docetaxel, a chemotherapy first approved in 1996. Pfizer’s chief executive, Albert Bourla, had previously highlighted the compound as a prospective growth driver later in the decade, and analysts had regarded the forthcoming data as a significant oncology catalyst.

Pfizer acquired the drug through its $43 billion purchase of biotech firm Seagen in 2023.

Source link